Fortrea has agreed to acquire the early-phase services division of fellow CRO Worldwide Clinical Trials for $45 million. | Fortrea has agreed to acquire the early-phase services division of fellow CRO ...
Teva Pharmaceutical's dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s ...
TScan Therapeutics will reduce its workforce by 75% following the pause of its hematological and autoimmune programs. | TCR-T ...
The SEC and the FDA have signed a three-year agreement to step up cooperation and information-sharing capabilities aiming to ...
Novartis has struck a deal worth up to $3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and ...
AI by itself isn’t enough to develop a compelling drug; the biology also has to check out. The science behind ABS-201 came to ...
As for Alnylam’s marketed med Amvuttra (vutrisiran), approved in ATTR-CM patients last March, the company itself used the ESC Congress to trumpet a subgroup analysis in its pivotal Helios-B trial ...
Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a preclinical trispecific antibody targeting B-cell-mediated diseases. | Roche is paying oncology-focused ...
About a year after halving its staff in a clinical push, Arsenal Biosciences is now making a hard pivot, laying off most of its employees and seeking new homes for its assets. ArsenalBio is turning to ...
Medtronic is recalling certain esophageal pH monitoring capsule delivery devices amid the risk of them failing whilst ...
Novocure has become the latest medtech company to be hit by a cyberattack, with the oncology specialist revealing that ...
GSK has linked its mRNA seasonal flu vaccine candidate to higher immune responses than conventional jabs in a phase 2 trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results